Robert Marcus
Stock Analyst at JP Morgan
(0.90)
# 3,152
Out of 4,829 analysts
21
Total ratings
45.45%
Success rate
-12.84%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Marcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PEN Penumbra | Maintains: Overweight | $230 → $285 | $297.55 | -4.22% | 3 | Feb 19, 2025 | |
| IART Integra LifeSciences Holdings | Upgrades: Neutral | $75 | $13.67 | +448.65% | 2 | Dec 17, 2021 | |
| BDX Becton, Dickinson and Company | Downgrades: Neutral | $265 | $175.34 | +51.13% | 10 | Aug 6, 2021 | |
| GKOS Glaukos | Downgrades: Underweight | $50 | $94.64 | -47.17% | 2 | Oct 8, 2020 | |
| TMDX TransMedics Group | Downgrades: Neutral | $15 | $118.73 | -87.37% | 2 | Oct 8, 2020 | |
| ATRC AtriCure | Maintains: Overweight | $48 → $57 | $31.81 | +79.19% | 2 | Jul 29, 2020 |
Penumbra
Feb 19, 2025
Maintains: Overweight
Price Target: $230 → $285
Current: $297.55
Upside: -4.22%
Integra LifeSciences Holdings
Dec 17, 2021
Upgrades: Neutral
Price Target: $75
Current: $13.67
Upside: +448.65%
Becton, Dickinson and Company
Aug 6, 2021
Downgrades: Neutral
Price Target: $265
Current: $175.34
Upside: +51.13%
Glaukos
Oct 8, 2020
Downgrades: Underweight
Price Target: $50
Current: $94.64
Upside: -47.17%
TransMedics Group
Oct 8, 2020
Downgrades: Neutral
Price Target: $15
Current: $118.73
Upside: -87.37%
AtriCure
Jul 29, 2020
Maintains: Overweight
Price Target: $48 → $57
Current: $31.81
Upside: +79.19%